Suchergebnisse - "Pavilack, Melissa"

PubPharm (17)

1

EGFR mutation testing and TKI treatment patterns among veterans with stage III and IV non-small cell lung cancer

enthalten in: Cancer treatment and research communications | 2021

von Hung, A. | Lee, K. | Alba, P. | +10

2

Real-world impact of brain metastases on healthcare utilization and costs in patients with non-small cell lung cancer treated with EGFR-TKIs in the US

enthalten in: Journal of medical economics | 2021

von Kong, A. | Pavilack, M. | Huo, H. | +6

3

Real-world disease burden and outcomes of brain metastases in EGFR mutation-positive non-small-cell lung cancer

enthalten in: Future oncology (London, England) | 2020

von Nadler, E. | Espirito, J. | Pavilack, M. | +2

4

EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors

enthalten in: BMC cancer | 2020

von Chiang, A. | Fernandes, A. | Pavilack, M. | +5

5

Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors

enthalten in: Advances in therapy | 2020

von Nadler, E. | Pavilack, M. | Espirito, J. | +2

6

Adverse event rates and economic burden associated with purine nucleoside analogs in patients with hairy cell leukemia : a US population-retrospective claims analysis

enthalten in: Orphanet journal of rare diseases | 2020

von Epperla, N. | Pavilack, M. | Olufade, T. | +5

7

The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2019

von Subramanian, J. | Fernandes, A. | Laliberté, F. | +3

8

Patient preferences for attributes of tyrosine kinase inhibitor treatments for EGFR mutation-positive non-small-cell lung cancer

enthalten in: Future oncology (London, England) | 2019

von Bridges, J. | la Cruz, M. | Pavilack, M. | +4

9

Treatment patterns and overall survival among patients with unresectable, stage III non-small-cell lung cancer

enthalten in: Future oncology (London, England) | 2019

von Bobbili, P. | Ryan, K. | Duh, M. | +4

10

Real-world treatment patterns among patients with unresected stage III non-small-cell lung cancer

enthalten in: Future oncology (London, England) | 2019

von Ryan, K. | Skinner, K. | Fernandes, A. | +4